Trade

with

Incyte Corp Ltd
(NASDAQ: INCY)
AdChoices
55.07
+0.12
+0.22%
After Hours :
55.07
0.00
0.00%

Open

54.48

Previous Close

54.95

Volume (Avg)

1.26M (955.78k)

Day's Range

53.76-55.93

52Wk Range

35.21-70.86

Market Cap.

9.27B

Dividend Rate ( Yield )

-

Beta

1.24

Shares Outstanding

168.41M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 354.95M

    • Net Income

    • -83.15M

    • Market Cap.

    • 9.27B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -36.53

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.24

    • Forward P/E

    • 104.17

    • Price/Sales

    • 24.10

    • Price/Book Value

    • -54.35

    • Price/Cash flow

    • -121.95

      • EBITDA

      • -14.99M

      • Return on Capital %

      • -26.79

      • Return on Equity %

      • -

      • Return on Assets %

      • -26.79

      • Book Value/Share

      • -1.02

      • Shares Outstanding

      • 168.41M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 79.67

        • Credit Rating

        • -

        • Analysts

        • 5

        • EPS Estimate

        • 0.36

        • Cashflow Estimate

        • 0.84

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -2.10

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 146.26

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 99.82

            • 82.75

            • Pre-Tax Margin

            • -36.45

            • 39.38

            • Net Profit Margin

            • -36.53

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -508.30

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 5.13

              • 2.92

              • Quick Ratio

              • 4.94

              • 2.35

              • Interest Coverage

              • -2.43

              • 38.02

              • Leverage Ratio

              • -

              • 2.21

              • Book Value/Share

              • -1.02

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -62.89

                • 217.39

                • P/E Ratio 5-Year High

                • -84.86

                • 634.30

                • P/E Ratio 5-Year Low

                • -6.35

                • 124.82

                • Price/Sales Ratio

                • 22.94

                • 9.52

                • Price/Book Value

                • -51.55

                • 8.61

                • Price/Cash Flow Ratio

                • -121.95

                • 50.51

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -26.79

                    (-25.30)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • 3.37

                  • 1.48

                  • Asset Turnover

                  • 0.73

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -16.10M
                  Operating Margin
                  -4.54
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -121.95
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  60.40%

                  Mutual Fund Ownership

                  65.49%

                  Float

                  65.03%

                  5% / Insider Ownership

                  1.66%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Health Care Fund

                  •  

                    9,591,143

                  • 95.66

                  • 5.70

                  • American Funds NVIT Growth

                  •  

                    6,281,800

                  • 0.00

                  • 3.73

                  • VA CollegeAmerica Growth Fund of America

                  •  

                    4,935,800

                  • 0.00

                  • 2.93

                  • VA CollegeAmerica Small Cap World

                  •  

                    4,445,600

                  • 0.00

                  • 2.64

                  • Bb Biotech AG

                  •  

                    4,301,867

                  • 3.32

                  • 2.55

                  • T. Rowe Price Health Sciences Fund

                  •  

                    3,638,300

                  • -17.12

                  • 2.16

                  • T. Rowe Price Growth Stock Fund

                  •  

                    3,112,072

                  • 20.53

                  • 1.85

                  • T. Rowe Price New Horizons Fund

                  •  

                    3,046,900

                  • -9.80

                  • 1.81

                  • T. Rowe Price Small Cap Stock Fund

                  •  

                    2,632,700

                  • -0.49

                  • 1.56

                  • Vanguard Mid-Cap Index Fund

                  •  

                    2,593,038

                  • 1.59

                  • 1.54

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • T. Rowe Price Associates, Inc.

                  •  

                    21,006,208

                  • -5.90%

                  • 12.48

                  • Capital World Investors

                  •  

                    17,663,200

                  • -0.03%

                  • 10.49

                  • Wellington Management Company, LLP

                  •  

                    16,231,351

                  • +106.85%

                  • 9.64

                  • Baker Bros Advisors LLC

                  •  

                    14,845,559

                  • +0.07%

                  • 8.82

                  • Vanguard Group, Inc.

                  •  

                    8,405,140

                  • +3.44%

                  • 4.99

                  • Jennison Associates LLC

                  •  

                    7,116,713

                  • +0.09%

                  • 4.23

                  • Bellevue Asset Management AG

                  •  

                    4,301,867

                  • +3.32%

                  • 2.55

                  • BB Biotech AG

                  •  

                    4,163,790

                  • +0.73%

                  • 2.47

                  • Artisan Partners Limited Partnership

                  •  

                    4,120,108

                  • -2.49%

                  • 2.45

                  • Franklin Advisers, Inc.

                  •  

                    3,835,110

                  • -1.08%

                  • 2.28

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  Mid Growth

                  Incyte Corp Ltd was incorporated in Delaware in 1991. It is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs to treat serious unmet medical needs. The Company...more’s pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI® (ruxolitinib). The Company’s drug discovery and development activities face, and will continue to face, intense competition from organizations such as pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies. The Company’s ongoing research and development activities and any manufacturing and marketing of JAKAFI and its product candidates are subject to extensive regulation by n...moreumerous governmental authorities in the United States and other countries. The Company’s trademaks include Incyte and JAKAFI. The Company’s operations are subject to various environmental, health and safety laws and regulations governing, among other things, the use, handling, storage and disposal of regulated substances and the health and safety of the employees.lessless

                  Key People

                  Mr. Herve Hoppenot

                  CEO/Director/President

                  Richard U. De Schutter

                  Chairman of the Board/Director

                  Julian C. Baker

                  Director/Vice Chairman of the Board

                  David C. Hastings

                  CFO/Executive VP

                  Paula J. Swain

                  Executive VP, Divisional

                  • Incyte Corp Ltd

                  • Experimental Station

                  • Wilmington, DE 19880

                  • USA.Map

                  • Phone: +1 302 498-6700

                  • Fax: +1 302 425-2750

                  • incyte.com

                  Incorporated

                  1991

                  Employees

                  481

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: